



04-02-02

Docket No: AHP-98031 P2
PatentLoc 0420
12
03CO*3
7/24/02IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: Ken Kees et al.
Serial No.: 10/068,711 Group Art No.:
Filed: February 6, 2002 Examiner:
For: New Acylresorcinol Derivatives Are Selective Vitronectin Receptor
Inhibitors
Confirmation No.:
Customer Number: 25291

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number ET302329999US addressed to the Commissioner for Patents, Washington, DC 20231.

3-29-02
Date
John R. Barker

2. Identification of Time of Filing

This Information Disclosure Statement

- a. ☒ is filed within three months of the filing date of the application.
- b. ☒ is filed before the mailing date of a first Office Action on the merits.
- c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. ☐ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. ☐ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. ☐ Certification under 37 CFR 1.97(e)
The undersigned attorney certifies

- a. ☐ that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. ☐ The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

☐ Newly Cited Information
A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed.

☒ Previously Cited Information
No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.
Prior application is Serial Number 09/291,558, filed on April 14 of 1999 for New Acylresorcinol Derivatives Are Selective Vitronectin Receptor Inhibitors.


- ☐ Concise Explanation
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
- b. ☐ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

- ☐ Fees
- ☐ Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00

Method of Payment of Fees:
Charge Deposit Account No. 01-1425 in the amount of \$0.00
A duplicate of this statement is enclosed.

Instructions as to Overpayment/Underpayment:
Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.



Michael R. Nagy
March 29, 2002
Reg. No. 33,432

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940-0874
Tel. No. (610) 902-2624

Substitute for form 1449/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/068,711
			Filing Date	February 6, 2002
			First Named Inventor	Ken Kee
			Group Art Unit	
			Examiner Name	
Sheet	1	of	Attorney Docket Number	AHP-98031 P2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	5,668,159		Fuqiang Jin et al.	09-16-1997	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	2.	WO	95/13262		Peter Astles et al.	05-18-1995		<input type="checkbox"/>
	3.	WO	95/32710		George Hartman et al.	12-07-1995		<input type="checkbox"/>
	4.	WO	96/00730		Fadia Ali et al.	01-11-1996		<input type="checkbox"/>
	5.	WO	96/06087		Chet Kwon et al.	02-29-1996		<input type="checkbox"/>
	6.	WO	96/26190		Thomas Wen-Fu Ku	08-29-1996		<input type="checkbox"/>
	7.	WO	96/37492		Matthew Voss et al.	11-28-1996		<input type="checkbox"/>
	8.	WO	97/08145		Peter Ruminski et al.	03-06-1997		<input type="checkbox"/>
	9.	WO	97/23451		Beate Diefenbach et al.	07-03-1997		<input type="checkbox"/>
	10.	WO	97/33887		Prabhakar Jadhav et al.	09-18-1997		<input type="checkbox"/>
	11.	WO	97/24119		William Miller et al.	07-10-1997		<input type="checkbox"/>
	12.	WO	97/24122		Fadia Ali et al.	07-10-1997		<input type="checkbox"/>
	13.	WO	97/24124		Fadia Ali et al.	07-10-1997		<input type="checkbox"/>
	14.	WO	97/34865		Serge Bernard et al.	09-25-1997		<input type="checkbox"/>
	15.	WO	97/35615		Robert Gould et al.	10-02-1997		<input type="checkbox"/>
	16.	WO	97/36859		Barbara Chen et al.	10-09-1997		<input type="checkbox"/>
	17.	WO	98/00480		Jae Lee et al.	01-08-1998		<input type="checkbox"/>
	18.	WO	98/14192		James Callahan et al.	04-09-1998		<input type="checkbox"/>
	19.	EPC	0 307 156		David Smith	03-15-1989		<input type="checkbox"/>
	20.	EPC	0 307 157		Tsuneyoshi Okada et al.	03-15-1989		<input type="checkbox"/>
	21.	EPC	0 320 032		Raymond Stokbroekx et al.	06-14-1989		<input type="checkbox"/>
	22.	EPC	0 796 855		Volkmar Wehner et al.	09-24-1997		<input type="checkbox"/>
	23.	EPC	0 820 988		Volkmar Wehner et al.	01-28-1998		<input type="checkbox"/>
	24.	EPC	0 820 991		Volkmar Wehner et al.	01-28-1998		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	25.	Sefton et al., Proc. Natl. Acad. Sci USA, 1992, 1557-1561, 89	<input type="checkbox"/>
	26.	Montgomery et al., Proc. Natl. Acad. Sci. USA, 1994, 8856-8860, 91	<input type="checkbox"/>
	27.	Brooks et al., Cell, 1994, 1157-1164, 79	<input type="checkbox"/>
	28.	Yun et al., Cancer Res., 1996, 3103-3111, 56	<input type="checkbox"/>
	29.	Brooks et al., Science, 1994, 569-571, 264	<input type="checkbox"/>
	30.	Adanis et al., Am. J. Ophthal., 1994, 445-450, 118	<input type="checkbox"/>
	31.	Hammes et al., Nature Med., 1996, 529-533, 2	<input type="checkbox"/>
	32.	Friedlander et al., Natl. Acad. Sci. USA, 1996, 9764-9769, 93	<input type="checkbox"/>
	33.	Peacock et al., J. Exp. Med., 1992, 1135-1138, 175	<input type="checkbox"/>
	34.	Choi et al., J. Vasc. Surgery, 1994, 125-134, 19	<input type="checkbox"/>
	35.	Matsumo et al., Circulation, 1994, 2203-2226, 90	<input type="checkbox"/>
	36.	White et al., Current Biology, 1993, 596-599, 3(9)	<input type="checkbox"/>
	37.	Davies et al., J. Cell Biol., 1989, 1817-1826, 109	<input type="checkbox"/>
	38.	Helfrich et al., J. Bone Mineral Res., 1992, 335-343, 7	<input type="checkbox"/>
	39.	Horton et al., Exp. Cell. Res., 1991, 368-375, 195	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number		10/068,711
				Filing Date		February 6, 2002
				First Named Inventor		Ken Kees
				Group Art Unit		
Examiner Name						
Sheet	2	of	2	Attorney Docket Number		AHP-98031 P2

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	40.	Fisher et al., Endocrinology, 1993, 1411-1413, 132	<input type="checkbox"/>
	41.	Engleman et al., J. Clin. Invest., 1997, 2284-2292, 99	<input type="checkbox"/>
	42.	Engleman et al., Annual Reports in Medicinal Chem., 1996, 191-200, 31	<input type="checkbox"/>



Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.